Effect of Antiresorptive Therapy on Osteoblastic and Osteoclastic Activity in Postmenopausal Osteoporosis Women

The awareness of osteoporosis has grown worldwide in recent years. This silently progressing metabolic bone disease is widely prevalent in India, and osteoporotic fractures are a common cause of morbidity and mortality in Indian women. Rapid bone loss occurs in postmenopausal women due to hormonal factors which lead to increased risk of fractures. Biochemical markers of bone metabolism are used to assess skeletal turnover and will be clinically useful in the management of post-menopausal osteoporosis women (PMO) as well as for assessing the effect of antiresorptive therapy. Aim: 1) To measure bone formation and resorption markers such as serum alkaline phosphatase and tartrate resistant acid phosphatase at the base line level in postmenopausal osteoporosis women & control. 2) These biochemical parameters were determined 3 months post antiresorptive therapy (alendronate + calcium + calcitriol) in postmenopausal osteoporosis patients. Study Design: Prospective Setting: Postmenopausal osteoporosis patients from civil hospital Sangli and Miraj. Participants: 60 clinically diagnosed postmenopausal osteoporosis patients and 60 normal subjects (postmenopausal nonosteoporosis women) were recruited as control. Results: Serum alkaline phosphatase and tartrate resistant acid phosphatase was significantly increased (P<0.001) in PMO as compared to controls and post therapy these levels were decreased significantly (P<0.001) in PMO. Conclusion: Biochemical markers of bone turnover provide information that can aid in predicting risk of future 208 Dr. Mrs. Jagtap Vanita Ramesh bone loss and osteoporotic fracture. These markers can also be used to monitor antiresorptive therapy in the PMO patients.